A phase II clinical study evaluating the efficacy and safety of neoadjuvant and adjuvant sunitinib in previously untreated patients with metastatic renal cell carcinoma (mRCC)(NeoSun).

Sarah Welsh,Kate Fife,Athena Matakidou,Jean Mullin,Andrea Machin,Wendi Qian,Victoria Ingleson,Katy Marie Dalchau,Pamela Whittaker,Anne Warren,Andrew N. Priest,Fulvio Zaccagna,Tristan Barrett,Ferdia A. Gallagher,Antony C.P. Riddick,James N. Armitage,T. Eisen

A phase II clinical study evaluating the efficacy and safety of neoadjuvant and adjuvant sunitinib in previously untreated patients with metastatic renal cell carcinoma (mRCC)(NeoSun).

2017

Sarah Welsh
Kate Fife
Athena Matakidou
Jean Mullin
Andrea Machin
Wendi Qian
Victoria Ingleson
Katy Marie Dalchau
Pamela Whittaker
Anne Warren
Andrew N. Priest
Fulvio Zaccagna
Tristan Barrett
Ferdia A. Gallagher
Antony C.P. Riddick
James N. Armitage
T. Eisen

e16087Background: Sunitinib improves clinical outcomes in patients (pts) with mRCC. The single arm phase II NeoSun trial was designed to investigate its added value to nephrectomy, and to explore t...

Keywords:

Pathology
Adjuvant
Renal cell carcinoma
Cancer research
Sunitinib
Medicine
clinical study
in patient
Oncology
Internal medicine
Nephrectomy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations